Business Context and Reporting Period
This Form 6-K filing by Ascendis Pharma A/S covers the month of June 2026. The report details the announcement of 5-year (Week 266) data from the Phase 2 PaTH Forward Trial for TransCon PTH (palopegteriparatide), a treatment for adults with hypoparathyroidism.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial results and does not contain financial statements.
Material Changes and Clinical Results
The primary material update is the long-term efficacy and safety data from the PaTH Forward Trial involving 59 adults (95% completion rate). Key Week 266 results include:
- Responder Rate: 82% of patients met the multi-component endpoint (normal serum calcium, no active vitamin D, and <600 mg/day calcium).
- Calcium Management: 88% achieved normal albumin-adjusted serum calcium (mean 9.0 mg/dL); 96% achieved independence from active vitamin D; 95% achieved independence from therapeutic calcium doses.
- Renal Function: Mean eGFR was 78.0 mL/min/1.73 m2, representing a sustained increase of 9.4 mL/min/1.73 m2 from baseline, contrasting with expected age-related decline.
- Bone Health: Mean BMD Z-scores corrected from high baseline levels and remained above 0 through Week 266.
- Quality of Life: Significant improvements in symptoms and health-related quality of life (HPES and SF-36 scores) were maintained.
Outlook, Risks, and Safety
Safety Profile: The treatment was generally well-tolerated with no new safety signals. Treatment-emergent adverse events were mostly mild or moderate, with no discontinuations related to the study drug. One patient developed transient, low-titer, non-neutralizing anti-PTH antibodies with no impact on safety or efficacy; no other patients developed antibodies over five years.
Outlook: The data demonstrates that TransCon PTH replicates the systemic actions of endogenous PTH with a balanced impact on the kidney, small intestine, CNS, and bone, enabling independence from conventional therapy.
Investor Verification Checklist
- Verify the regulatory pathway and timeline for potential FDA/EMA approval based on these 5-year Phase 2 data.
- Confirm the commercial launch strategy and pricing assumptions for TransCon PTH in the hypoparathyroidism market.
- Review the company's cash burn rate and capital requirements, as this filing contains no financial liquidity data.
- Assess the competitive landscape for hypoparathyroidism treatments relative to the demonstrated independence from active vitamin D and calcium.